Ocugen to Acquire Liminal BioSciences for $10M
Ticker: OCGN · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, financing
TL;DR
Ocugen buying Liminal BioSciences for $10M, closing Q2 2024.
AI Summary
Ocugen, Inc. announced on April 8, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of Liminal BioSciences Inc. for an aggregate purchase price of $10 million. This acquisition is expected to close in the second quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition could expand Ocugen's pipeline and therapeutic capabilities, potentially leading to new treatment options and market opportunities.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks related to integration, regulatory approval, and market reception of the acquired assets.
Key Numbers
- $10.0M — Acquisition Price (Aggregate purchase price for Liminal BioSciences Inc.)
Key Players & Entities
- Ocugen, Inc. (company) — Acquiring company
- Liminal BioSciences Inc. (company) — Acquired company
- $10 million (dollar_amount) — Aggregate purchase price
- April 8, 2024 (date) — Announcement date
- second quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces Ocugen, Inc.'s entry into a definitive agreement to acquire Liminal BioSciences Inc.
What is the total purchase price for the acquisition?
The aggregate purchase price for the acquisition of Liminal BioSciences Inc. is $10 million.
When is the acquisition expected to close?
The acquisition is expected to close in the second quarter of 2024.
What are the key conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the ticker symbol for Ocugen, Inc.?
Ocugen, Inc. is identified by Central Index Key 0001372299 and SEC File Number 001-36751, and its business address is in Malvern, Pennsylvania.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-04-08 13:13:16
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq Sto
Filing Documents
- ocgn-20240408.htm (8-K) — 28KB
- ocgn-20240408xex991.htm (EX-99.1) — 14KB
- 0001628280-24-015171.txt ( ) — 167KB
- ocgn-20240408.xsd (EX-101.SCH) — 2KB
- ocgn-20240408_lab.xml (EX-101.LAB) — 21KB
- ocgn-20240408_pre.xml (EX-101.PRE) — 12KB
- ocgn-20240408_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 8, 2024, Ocugen, Inc. ("Ocugen") issued a press release announcing the U.S. Food and Drug Administration (FDA) has cleared Ocugen's Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. The following exhibits are being filed herewith: (d) Exhibits Exhibit No. Document 99.1 Press Release of Ocugen, Inc. dated April 8 , 202 4 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 8, 2024 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder 2